Linked Life Data

7461569

Source:http://linkedlifedata.com/resource/pubmed/id/7461569

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
45
pubmed:dateCreated
1981-4-13
pubmed:abstractText
Clofibrate was administered to 5 selected outpatients suffering from type IIa hyperlipoproteinaemia who had previously undergone dietetic treatment, and one female patient suffering from hypo-HDL-aemia in order to elucidate the question as to whether medium long term clofibrate therapy apart from producing an initial increase relative to the LDL concentration may also lead to an absolute increase in the concentration of HDL cholesterol in serum. According to our findings daily doses of 1 to 2 g clofibrate increase the concentrations of HDL cholesterol and phospholipids within two to four months after therapy was started. These increases remained unchanged within four to eight weeks after having reduced the dose to half its original level. Subsequent HDL cholesterol levels still range above those of the controls prior to clofibrate treatment. After a further clofibrate dose at the original dose level it takes again four to eight weeks until the HDL cholesterol level increases again. Thus, during medium long term therapy the quantitative effect of clofibrate on the lipoprotein pattern is similar to that of bezafibrate and etofibrate. It is only the latency period of an increase in serum concentration of HDL cholesterol that differs: it is longest for clofibrate, shortest for etofibrate, with bezafibrate obviously being right in the middle.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0015-8178
pubmed:author
pubmed:issnType
Print
pubmed:day
4
pubmed:volume
98
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1761-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1980
pubmed:articleTitle
[Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
pubmed:publicationType
Journal Article, English Abstract